Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

Data from the Phase II non-responder study were presented on April 15, 2007 at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) held in Barcelona, Spain and on May 21, 2007 at Digestive Disease Week (DDW) 2007 held in Washington, DC.

On June 26, 2007, Schering-Plough advised us that they would not be entering into a second period of exclusivity to negotiate the terms of a license agreement for celgosivir at that time. MIGENIX is now in various stages of discussions with other interested parties for the partnering of celgosivir.

A Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection who have not received prior treatment for their infection is ongoing. The focus of this study is on viral kinetics, pharmacokinetics, safety and tolerability of celgosivir in combination with peginterferon alfa-2b with ribavirin. As reported previously, enrollment in the study has been slower than anticipated. Interim 4-week data from the study are expected in approximately 10 patients in October 2007, with guidance for 12-week data to be provided in conjunction with the 4-week data.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. An Investigational New Drug (IND) application is planned to be submitted to the US FDA in the first quarter of 2008 for the future development of celgosivir.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, is conducting a Phase II rosacea clinical trial in the United States. The Phase II trial is a randomized, vehicle-controlled, double-blind, multi-center study designed to evaluate the safety and
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Technology Applications International Corporation (the "Company" ... subsidiary Renuell Int,l, Inc. has signed an additional exclusive ... ("NASA") at the Johnson Space Center in ... tapplic.com/houstonphotos/ Charles J. ... to announce our latest, exclusive agreement with NASA. In ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ("Angiotech") (NASDAQ: ... and medical device company, today announced that ... (the "Tender Offer"),for its outstanding Senior Floating ... "First Priority Notes"), and its outstanding 7.75% ...
... breadth of experience and business expertise, SCOTTSDALE, ... technology company that markets the Provant(R) Wound Therapy,System, ... its Board of,Directors. The two new directors are ... and Charles "Chuck" S. Lunden, a principal with,Bederson ...
... ... the job done, NEWARK, N.J., Aug. 22 BioNeutral announced ... its,Ogiene(TM) FE technology to bring 10,000 mobile homes into full compliance,so ... in need,of biohazard-free housing., Dr. Andy Kielbania, Chief Scientist at ...
Cached Biology Technology:Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 2Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 3Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 4Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 5Regenesis Biomedical Announces Additions to Board of Directors 2BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana 2
(Date:9/2/2014)... is enough to prevent Type 2 diabetes, don,t get your ... of The FASEB Journal , suggests that ... diabetes. This study compared genetically identical twins-one heavier and one ... metabolites, including those related to Type 2 diabetes, were found ... suggest that the onset of this type of diabetes is ...
(Date:9/2/2014)... published in the September issue of The ... novel strategy to diagnose the leading cause of ... damage has occurred. This advance involves quantifying the ... endothelium of retinal vessels. Using new probes developed ... early molecular development of diabetic retinopathy. , "My ...
(Date:9/2/2014)... as perching birds, that migrate by night tend to ... to reach their destinations. This seasonal difference in flight ... short migratory flights, says researcher Cecilia Nilsson of Lund ... and Sociobiology . , Nilsson, in a group ... to measure over three years the speed by which ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Migrating birds sprint in spring, but take things easy in autumn 2
... new study finds that Caribbean seaweeds are far better competitors ... this triumph is bad news for Caribbean coral reefs. ... the living corals that build reefs and contribute startling white ... environment but in fact a battle is constantly waged between ...
... Obama has made cyber security an integral issue when ... ensure that the U.S. remains on the cutting edge, ... will convene a gathering of the nation,s top minds ... issues affecting the economy and United States, national security. ...
... Smith, Ph.D., Wellcome Trust Principal Research Fellow and ... Fellow of Emmanuel College, Cambridge, has been bestowed ... Award, recognizing exemplary leadership in the international microbiological ... University of Virginia, says Smith is "internationally recognized ...
Cached Biology News:Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 2Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 3The American Society for Microbiology honors Geoffrey L. Smith 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
...
Biology Products: